Collectively, these data suggested that a PROTAC-based strategy is an option for abrogating both the kinase-dependent and -independent cancer-enabling activities of LZK but that additional optimization, especially regarding cell permeability, is required for application in vivo. This evidence concerns the gene MAP3K13 and cancer.